Long-term treatment of psychotic (delusional) depression with fluvoxamine: An open pilot study

R. Zanardi, L. Franchini, M. Gasperini, E. Smeraldi, J. Perez

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

The aim of this open pilot study was to evaluate the efficacy of fluvoxamine in the continuation as well as in the maintenance therapy of delusional depression. Thirty patients with recurrent, unipolar depression (DSM-IV criteria) were selected who had had at least one depressive episode during the 18 months preceding the delusional depressive index episode and were treated with fluvoxamine 300 mg/day. Twenty-five of them had a sustained response to this short-term treatment and agreed to enter into the 30-month follow up study All participants completed the follow up period. No relapse was observed during the 6 months of continuation therapy. During the further 24 months of maintenance therapy, 80% of the patients remained well, whereas 20% (five out of 25) had a single recurrence. Based on these observations, fluvoxaminc might be a promising drug for long-term therapy of delusional depression. Further controlled studies are required to confirm this finding.

Original languageEnglish
Pages (from-to)195-197
Number of pages3
JournalInternational Clinical Psychopharmacology
Volume12
Issue number4
Publication statusPublished - 1997

Fingerprint

Fluvoxamine
Depression
Therapeutics
Recurrence
Depressive Disorder
Diagnostic and Statistical Manual of Mental Disorders
Pharmaceutical Preparations

Keywords

  • Continuation treatment
  • Fluvoxamine
  • Maintenance treatment
  • Psychotic (delusional) depression

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Pharmacology (medical)
  • Neuroscience(all)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Zanardi, R., Franchini, L., Gasperini, M., Smeraldi, E., & Perez, J. (1997). Long-term treatment of psychotic (delusional) depression with fluvoxamine: An open pilot study. International Clinical Psychopharmacology, 12(4), 195-197.

Long-term treatment of psychotic (delusional) depression with fluvoxamine : An open pilot study. / Zanardi, R.; Franchini, L.; Gasperini, M.; Smeraldi, E.; Perez, J.

In: International Clinical Psychopharmacology, Vol. 12, No. 4, 1997, p. 195-197.

Research output: Contribution to journalArticle

Zanardi, R, Franchini, L, Gasperini, M, Smeraldi, E & Perez, J 1997, 'Long-term treatment of psychotic (delusional) depression with fluvoxamine: An open pilot study', International Clinical Psychopharmacology, vol. 12, no. 4, pp. 195-197.
Zanardi, R. ; Franchini, L. ; Gasperini, M. ; Smeraldi, E. ; Perez, J. / Long-term treatment of psychotic (delusional) depression with fluvoxamine : An open pilot study. In: International Clinical Psychopharmacology. 1997 ; Vol. 12, No. 4. pp. 195-197.
@article{db4b00a91ea84668ac80b91efbdea988,
title = "Long-term treatment of psychotic (delusional) depression with fluvoxamine: An open pilot study",
abstract = "The aim of this open pilot study was to evaluate the efficacy of fluvoxamine in the continuation as well as in the maintenance therapy of delusional depression. Thirty patients with recurrent, unipolar depression (DSM-IV criteria) were selected who had had at least one depressive episode during the 18 months preceding the delusional depressive index episode and were treated with fluvoxamine 300 mg/day. Twenty-five of them had a sustained response to this short-term treatment and agreed to enter into the 30-month follow up study All participants completed the follow up period. No relapse was observed during the 6 months of continuation therapy. During the further 24 months of maintenance therapy, 80{\%} of the patients remained well, whereas 20{\%} (five out of 25) had a single recurrence. Based on these observations, fluvoxaminc might be a promising drug for long-term therapy of delusional depression. Further controlled studies are required to confirm this finding.",
keywords = "Continuation treatment, Fluvoxamine, Maintenance treatment, Psychotic (delusional) depression",
author = "R. Zanardi and L. Franchini and M. Gasperini and E. Smeraldi and J. Perez",
year = "1997",
language = "English",
volume = "12",
pages = "195--197",
journal = "International Clinical Psychopharmacology",
issn = "0268-1315",
publisher = "Lippincott Williams and Wilkins",
number = "4",

}

TY - JOUR

T1 - Long-term treatment of psychotic (delusional) depression with fluvoxamine

T2 - An open pilot study

AU - Zanardi, R.

AU - Franchini, L.

AU - Gasperini, M.

AU - Smeraldi, E.

AU - Perez, J.

PY - 1997

Y1 - 1997

N2 - The aim of this open pilot study was to evaluate the efficacy of fluvoxamine in the continuation as well as in the maintenance therapy of delusional depression. Thirty patients with recurrent, unipolar depression (DSM-IV criteria) were selected who had had at least one depressive episode during the 18 months preceding the delusional depressive index episode and were treated with fluvoxamine 300 mg/day. Twenty-five of them had a sustained response to this short-term treatment and agreed to enter into the 30-month follow up study All participants completed the follow up period. No relapse was observed during the 6 months of continuation therapy. During the further 24 months of maintenance therapy, 80% of the patients remained well, whereas 20% (five out of 25) had a single recurrence. Based on these observations, fluvoxaminc might be a promising drug for long-term therapy of delusional depression. Further controlled studies are required to confirm this finding.

AB - The aim of this open pilot study was to evaluate the efficacy of fluvoxamine in the continuation as well as in the maintenance therapy of delusional depression. Thirty patients with recurrent, unipolar depression (DSM-IV criteria) were selected who had had at least one depressive episode during the 18 months preceding the delusional depressive index episode and were treated with fluvoxamine 300 mg/day. Twenty-five of them had a sustained response to this short-term treatment and agreed to enter into the 30-month follow up study All participants completed the follow up period. No relapse was observed during the 6 months of continuation therapy. During the further 24 months of maintenance therapy, 80% of the patients remained well, whereas 20% (five out of 25) had a single recurrence. Based on these observations, fluvoxaminc might be a promising drug for long-term therapy of delusional depression. Further controlled studies are required to confirm this finding.

KW - Continuation treatment

KW - Fluvoxamine

KW - Maintenance treatment

KW - Psychotic (delusional) depression

UR - http://www.scopus.com/inward/record.url?scp=0030829073&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030829073&partnerID=8YFLogxK

M3 - Article

C2 - 9347379

AN - SCOPUS:0030829073

VL - 12

SP - 195

EP - 197

JO - International Clinical Psychopharmacology

JF - International Clinical Psychopharmacology

SN - 0268-1315

IS - 4

ER -